Adeona appoints Jeff Riley chair
This article was originally published in Scrip
Adeona Pharmaceuticals, a company developing innovative medicines for the treatment of serious central nervous system diseases, has made Jeff Riley its independent, non-executive chair of the board. Mr Riley has been a director at Adeona since March 2010, and takes over the role from CEO Dr James Kuo. Mr Riley is currently managing director of 526 Ventures, a life science consulting firm. He has previously served in a number of big pharma companies, including Pfizer.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.